This page lists 20 deals announced between January 4 and October 16, 2026 in which a drugmaker partnered with an AI company. Only three of the 20 disclosed a clean upfront payment: $115 million from Lilly to Insilico Medicine, $40 million from AstraZeneca to insitro, and $30 million from Zealand Pharma to Generate Biomedicines. Seven disclosed no financial terms at all, including every deal with OpenAI and Anthropic. The list is as of November 13, 2026 and is not exhaustive.
Drug Discovery and Licensing Deals
"Near-term" means the company reported one figure that mixes the upfront payment with early milestones or fees. "Total" is the headline value if every milestone is met. Royalties are extra in most of these deals.
| Date, 2026 | Drugmaker | AI company | Upfront or near-term | Milestones or total | Scope | Source |
|---|---|---|---|---|---|---|
| Jan 4 | Servier | Insilico Medicine | Up to $32M in upfront and near-term R&D payments | Total up to $888M | Oncology discovery | BioSpectrum Asia |
| Early Jan | Eli Lilly | Nimbus Therapeutics | $55M in upfront and near-term milestones | Total up to about $1.3B | Oral obesity drug, computational chemistry | Nimbus release |
| Jan 8 | GSK | Noetik | $50M in upfront and near-term milestones | Annual licence fees, amount not disclosed | Five-year non-exclusive licence to cancer foundation models | Business Wire |
| Jan 8 | Pfizer | Boltz | Not disclosed | Not disclosed | Exclusive models for structure prediction, affinity and biologics design | Boltz release |
| January | Servier | Iktos | Not broken out | Total above €1B, including upfront, research funding and milestones | Small molecules in oncology and neurology | pharmaphorum |
| January | Eli Lilly | Chai Discovery | Not disclosed | Not disclosed | Biologics design, plus a model built only for Lilly | GEN |
| Jan 20 | Johnson & Johnson | Isomorphic Labs | Not disclosed | Not disclosed | Multi-target research across several drug types | Isomorphic Labs |
| Feb 9 | Takeda | Iambic Therapeutics | Not disclosed | Milestone-based payments above $1.7B | Small molecules in cancer, gastrointestinal and inflammatory disease | pharmaphorum |
| Mar 29 | Eli Lilly | Insilico Medicine | $115M upfront | Total about $2.75B | Licence to preclinical oral drugs, plus joint programmes | Insilico release |
| Jun 22 | SK Biopharmaceuticals | Insilico Medicine | Up to $18M in upfront and near-term milestones | Total above $2.5B | Neuroimmune disorders of the central nervous system | Insilico release |
| Jul 2 | Takeda | Insilico Medicine | About $60M in initiation fees, near-term payments and milestones | Total about $600M | Discovery across Takeda's therapeutic areas | Insilico release |
| Jul 30 | GSK | Relation Therapeutics | Not broken out | Up to $110M in upfront and milestones combined | Human cell datasets for immunology, fibrosis and osteoarthritis | BioXconomy |
| Sep 21 | AbbVie | Iambic Therapeutics | Not disclosed | Not disclosed | Small molecules in immunology, neuroscience and oncology | AbbVie |
| Oct 13 | Zealand Pharma | Generate Biomedicines | $30M upfront, plus up to $35M in early preclinical milestones | Total milestones of nearly $1.2B | Two protein drug programmes for obesity and metabolic disease | Generate release |
| Oct 15 to 16 | AstraZeneca | insitro | $40M upfront | Up to about $1.46B in milestones | MASH and cardiomyopathies | BioXconomy |
Compute, Platform and Enterprise Deals
These are not licensing deals. No molecule changes hands and there are no milestones. The two dollar figures are spending commitments.
| Date, 2026 | Drugmaker | AI company | Disclosed value | Scope | Source |
|---|---|---|---|---|---|
| Jan 12 | Eli Lilly | Nvidia | Up to $1B over five years, invested jointly | Co-innovation lab in the San Francisco Bay Area | Nvidia |
| Apr 14 | Novo Nordisk | OpenAI | Not disclosed | AI across discovery, manufacturing, supply chain and commercial work | Novo Nordisk release |
| Apr 22 | Merck | Google Cloud | Up to $1B, multi-year | Gemini Enterprise across R&D, manufacturing, commercial and corporate functions | Constellation Research |
| May 20 | Bristol Myers Squibb | Anthropic | Not disclosed | Claude for more than 30,000 employees | Fierce Biotech |
| Sep 16 | Novo Nordisk | Anthropic | Not disclosed | Claude models and Claude Science in R&D | Euronews |
What the List Shows
- The cash paid at signing is a small share of the headline. By our arithmetic, Lilly's $115 million is about 4% of the $2.75 billion Insilico total. AstraZeneca's $40 million is under 3% of the roughly $1.5 billion insitro could receive. See biobucks for how to read these figures.
- Insilico signed four of the 20. Its four 2026 deals carry headline totals that add up to about $6.7 billion, against about $225 million in upfront and near-term payments, by our arithmetic on the company's own figures.
- The frontier labs disclose no money. OpenAI's and Anthropic's pharma deals are software and model access agreements with no published value. Details are on the OpenAI and Novo Nordisk and Anthropic partnerships pages.
- Lilly appears four times. Nimbus, Chai Discovery, Nvidia and Insilico. The Nvidia deal is covered on the Nvidia and Lilly lab page.
Conflicts and Gaps
- SK Biopharmaceuticals and Insilico: the release headline says "up to" $2.5 billion and its body says the value "exceeds" $2.5 billion. pharmaphorum described the $18 million as an upfront payment, while the release calls it upfront and near-term milestones combined.
- Merck and Google Cloud: Constellation Research dated the announcement April 22, 2026 and IT Brief dated it April 24. Coverage also differs on the length of the commitment.
- AstraZeneca and insitro: reports give October 15 or October 16.
- Takeda and Iambic: the upfront amount was not disclosed. The $1.7 billion figure is milestones only.
Methodology
Deals were included if they were announced in 2026, paired a drugmaker with a company that describes its platform as AI or computational, and had a company release or trade report we could open. Figures come from the linked source in each row. Where we could not open a company release, the row cites trade coverage, including Biotechgate and pharmaphorum roundups. Percentages are our own arithmetic. This page reports announced terms and is not investment advice. Status as of November 13, 2026.